amino.floamino.flo Facebook ad: “7 peptides. One FDA hearing.”
Ran for 3 days, from July 16 to July 19, 2026, the last day Crush saw it.
Run by amino.flo on Instagram. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)
Want an ad like this for your product?
Crush makes new ad images for your product from this ad: your logo, your product photo, your offer.
Trials from $19.95 USD, then $79.95 USD a month. Cancel anytime.
About this ad
- Meta Ad Library ID
- 1714321922941458
- Platforms
- Relaunches
- 0
Ad text
7 peptides. One FDA hearing. A decision that shapes the future of research peptides. 🧬 On July 23–24, 2026, an FDA advisory committee reviews seven of the most-used research peptides — and the outcome shapes how they can legally exist in the US. Here’s who’s on the docket, what’s actually being decided, and why the twist matters. 👉 Want the live tracker as it unfolds? Comment “FLO” for our free research Discord. 🧪 Not medical advice. Educational & research purposes only. 📖 First, the problem this is trying to solve. For years, popular peptides have lived in a legal gray zone — prepared by some compounding pharmacies, sold “for research” online, and shipped from overseas suppliers with little oversight. “Gray market” = sales through channels outside official, regulated distribution, often with far less accountability on purity and identity. The result: real demand, unclear rules, inconsistent quality. This hearing is the system finally trying to draw a clear line — one way or the other. Not medical advice. Educational purposes only. 📖 What’s actually being reviewed: the “503A” list. 503A is the section of federal law covering traditional pharmacy compounding — customized medications made for an individual patient. For a peptide with no FDA-approved version to be legally compounded, it generally needs to be on the FDA’s 503A Bulks List. Making that list is the difference between “compoundable” and “not.” So this committee — the Pharmacy Compounding Advisory Committee (PCAC) — is deciding whether to recommend adding these 7. It’s the legal path forward, drawn in real time. Not medical advice. Educational purposes only. 📖 Day 1 (July 23): the “repair” peptides. Four peptides, reviewed for the uses submitted to the FDA (these are the nominated uses under review — not endorsements): - BPC-157 — nominated around gut / ulcerative-colitis research. - KPV — a short tripeptide studied for anti-inflammatory, immune signaling. - TB-500 — a thymosin β-4 fragment studied for wound healing. - MOTS-c — a mitochondrial-derived peptide studied in metabolic research. The FDA’s question isn’t “do these work?” — it’s whether they meet the legal and characteriza
